Rise of AI continues to re-write life sciences IP strategies in 2022
A spate of pharma-high tech innovation partnerships have dominated opening days of the year
A spate of pharma-high tech innovation partnerships have dominated opening days of the year
Lighting firm Signify and panel-maker Samsung Display each acquired portfolios from one of Japan’s leading IP dealmakers last month
Saturday Opinion: Technology solutions that have helped the world through the pandemic would look very different absent a sophisticated IP licensing ecosystem, argues Dolby GC Andy Sherman
Dozens of communications patents changing hands in latest monetisation move from Chinese telecoms giant
12 November 2021
Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum
05 November 2021
Creation of an “open technology bank” for fee-based use comes as world’s third-biggest PCT filer also does more deals with NPEs
05 November 2021
Cipher, Unified Patents, RPX, Aon and Google Patents come together for the public launch of SPIF
02 November 2021
The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine
02 November 2021
In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales
01 November 2021
Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook
29 October 2021
New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets
22 October 2021
More than 200 assets change hands in the aftermath of a similarly-sized sale to delivery service Instacart
21 October 2021
Diagnostic innovation buyouts drive resurgence of med-tech deal-making
19 October 2021
Get unlimited access to all IAM content